Clinical decision engine
RapidPEP
High-speed clinical decision engine for HIV post-exposure prophylaxis. Evidence-based regimen selection, eligibility assessment, and monitoring protocol generation — in under two seconds.
CDC 2024 compliantAAHIVP-curatedOpen-source
01
The Exposure Protocol
Step through a structured eligibility assessment. The engine maps exposure characteristics to CDC-recommended PEP regimens in real time.
rapidpep — terminal
RAPIDPEP v1.0 — HIV Post-Exposure Prophylaxis Decision Engine
CDC guidelines compliant | AAHIVP-curated knowledge base
───
02
Clinical Credentialing
Built by a board-certified HIV pharmacist (AAHIVP). Every decision path is audited against current DHHS and CDC guidelines.
AAHIVP credentialed
American Academy of HIV Pharmacists
CDC guidelines
2024 PEP update compliant
Evidence base
53 peer-reviewed sources indexed
Response time
< 2 seconds to regimen output
03
The Prophylaxis Ledger
Complete drug regimen, dosing schedule, and clinical monitoring requirements for standard 3-drug PEP.
| Agent | Dose | Frequency | Duration |
|---|---|---|---|
| Tenofovir DF (TDF) | 300 mg | Once daily | 28 days |
| Emtricitabine (FTC) | 200 mg | Once daily | 28 days |
| Dolutegravir (DTG) | 50 mg | Once daily | 28 days |
| — Alternative: Raltegravir (RAL) | 400 mg | Twice daily | 28 days |
| — Alternative: Darunavir / Ritonavir | 800 / 100 mg | Once daily | 28 days |
Monitoring Protocol
| Test | Baseline | Follow-up |
|---|---|---|
| HIV Ag/Ab (4th gen) | Day 0 | 4-6 wk, 3 mo |
| Serum creatinine / eGFR | Day 0 | Week 2, Month 1 |
| CBC with differential | Day 0 | Month 1 |
| HBsAg, HCV antibody | Day 0 | — |
| ALT / AST | Day 0 | Week 2 |
| Pregnancy test | Day 0 | As indicated |
This tool is for educational and clinical decision support purposes only. Always consult current DHHS and CDC guidelines before initiating PEP. Clinical judgment by a qualified healthcare provider remains essential.